Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Department of Clinical Epidemiology, Hyogo College of Medicine, Hyogo, Japan.
Ann Thorac Surg. 2023 Dec;116(6):1195-1203. doi: 10.1016/j.athoracsur.2023.01.028. Epub 2023 Feb 2.
There is a paucity of data regarding shorter life expectancy after aortic valve replacement (AVR) in patients with severe aortic stenosis (AS).
Among 3815 patients with severe AS enrolled in the CURRENT AS (Contemporary outcomes after sURgery and medical tREatmeNT in patients with severe Aortic Stenosis) registry, there were 1469 patients (initial AVR: n = 647; conservative strategy: n = 822) with low surgical risk, 1642 patients (initial AVR: n = 433; conservative strategy: n = 1209) with intermediate surgical risk, and 704 patients (initial AVR: n = 117; conservative strategy: n = 587) with high surgical risk. Among 1163 patients who actually underwent surgical AVR as the initial strategy, patients were divided into 4 groups according to age <65 years (n = 185), 65 to 74 (n = 394), 75 to 80 (n = 345), and >80 (n = 239). The expected survival of the general Japanese population was obtained from the Statistics Bureau of Japan. The surgical risk was estimated using The Society of Thoracic Surgery (STS) score.
The median follow-up was 3.7 years. The cumulative incidences of all-cause death were significantly lower in the initial AVR strategy than in the initial conservative strategy across the 3 STS groups. Shorter life expectancy after surgical AVR was seen especially in younger patients. The observed mortality in low-risk patients was comparable to the expected mortality across all the age-groups, while intermediate-risk patients aged <75 years, and high-risk patients across all age-groups had higher mortality compared with the expected mortality.
The risk stratification according to age and STS score might be useful to estimate shorter life expectancy after AVR, and these findings have implications for decision making in the choice of surgical or transcatheter AVR.
在严重主动脉瓣狭窄(AS)患者中,主动脉瓣置换术(AVR)后预期寿命较短的数据很少。
在 CURRENT AS(严重主动脉瓣狭窄患者手术后的当代结局和药物治疗)登记研究的 3815 名严重 AS 患者中,有 1469 名患者(初始 AVR:n=647;保守策略:n=822)具有低手术风险,1642 名患者(初始 AVR:n=433;保守策略:n=1209)具有中等手术风险,704 名患者(初始 AVR:n=117;保守策略:n=587)具有高手术风险。在 1163 名实际接受初始手术 AVR 的患者中,根据年龄<65 岁(n=185)、65-74 岁(n=394)、75-80 岁(n=345)和>80 岁(n=239)将患者分为 4 组。从日本统计局获得普通日本人口的预期生存情况。使用胸外科医师学会(STS)评分估计手术风险。
中位随访时间为 3.7 年。在所有 STS 组中,初始 AVR 策略的全因死亡率明显低于初始保守策略。手术 AVR 后预期寿命缩短尤其见于年轻患者。低危患者的观察死亡率与所有年龄组的预期死亡率相当,而<75 岁的中危患者和所有年龄组的高危患者的死亡率均高于预期死亡率。
根据年龄和 STS 评分进行风险分层可能有助于估计 AVR 后的预期寿命较短,这些发现对手术或经导管 AVR 选择的决策有影响。